Virtus LifeSci Biotech Clinical Trials ETF (BBC)

NYSEARCA: BBC · IEX Real-Time Price · USD
0.00 (-0.01%)
At close: Dec 5, 2023, 2:34 PM
-0.06 (-0.27%)
After-hours: Dec 5, 2023, 8:00 PM EST
Assets $8.83M
Expense Ratio 0.79%
PE Ratio n/a
Shares Out n/a
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return -17.97%
Volume 428
Open 20.64
Previous Close 20.63
Day's Range 20.63 - 20.66
52-Week Low 16.88
52-Week High 28.74
Beta n/a
Holdings 114
Inception Date Dec 16, 2014

About BBC

Fund Home Page

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is issued by Virtus Investment Partners.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol BBC
Index Tracked LifeSci Biotechnology Clinical Trials Index

Top 10 Holdings

21.04% of assets
Name Symbol Weight
Bny Mellon Cash Reserve Usd n/a 2.98%
Revolution Medicines, Inc. RVMD 2.64%
CymaBay Therapeutics, Inc. CBAY 2.52%
Structure Therapeutics Inc. GPCR 2.24%
Immunovant, Inc. IMVT 2.07%
MoonLake Immunotherapeutics MLTX 1.90%
Crinetics Pharmaceuticals, Inc. CRNX 1.77%
Nuvalent, Inc. NUVL 1.68%
Mirati Therapeutics, Inc. MRTX 1.67%
Arcellx, Inc. ACLX 1.57%
View More Holdings


Ex-Dividend Amount Pay Date
Dec 20, 2017 $0.29724 Dec 27, 2017
Dec 21, 2015 $0.14733 Dec 29, 2015
Full Dividend History


ALPS' Biotech ETF SBIO Week's Top Performer

In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...

8 months ago - ETF Trends

Biotech ETFs Are Making a Comeback

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech ...

Other symbols: BBPSBIOXBI
1 year ago - ETF Trends

Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point

Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS:...

Other symbols: XBI
1 year ago - ETF Trends

Size Up SBIO as Biotech Catalysts Emerge

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

Betting on Biotech Bear Market Expiration Date

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

Positioning for Biotech Bounceback

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

Biotech Stocks, ETFs Starting to Look Healthier

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

SBIO Is a Good Place to Be for Biotech Innovation

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...

Other symbols: BBHIBBSBIO
1 year ago - ETF Trends

Biotech M&A Could Finally Perk Up in 2022

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, ma...

Other symbols: BBHIBBSBIO
2 years ago - ETF Trends

Smaller Biotech Stocks Ready to Perk Up

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more re...

Other symbols: SBIOBBHIBB
2 years ago - ETF Trends

Biotech Stocks Have Colds, but They Can Heal

This year hasn't been kind to biotechnology stocks and related exchange traded funds. The headwinds faced by these assets were ratcheted up last week when the Biden administration revealed plans to pu...

Other symbols: SBIOBBHIBB
2 years ago - ETF Trends

Finding Synergy With SPY

Looking for the perfect partner for the world's largest ETF.

2 years ago - ETFcom

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...

2 years ago - GuruFocus

Betting on Biotech With Utility Beyond Covid-19

The ALPS Medical Breakthroughs ETF (SBIO) is one of many biotechnology ETF garnering attention this year amid the race to defeat the coronavirus, but SBIO also offers investors allure that will extend...

Other symbols: IBBSBIO
3 years ago - ETF Trends

Novavax's 30% surge boosts biotech ETFs to best day in weeks

Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.

Other symbols: NVAXGERM
3 years ago - Market Watch

Biotech ETFs Gain Amid Vaccine Optimism

With a slew of news to start off the month and quarter, biotech equities and ETFs are moving higher on Wednesday with optimism over developments on the coronavirus vaccine front. The Dow Jones Industr...

Other symbols: BBHIBB
3 years ago - ETF Trends

3 ETFs With Q2 Gains Of At Least 30%

The S&P 500 is sitting on an impressive 16.36% gain with just one day left in the second quarter.

Other symbols: ACESARGT
3 years ago - Benzinga

Biotech ETFs in the Spotlight, Why They’ll Remain There

Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish ...

Other symbols: IBBSBIO
3 years ago - ETF Trends

Biotechnology Sector ETFs Are Leading the Charge

Biotechnology sector-related exchange traded funds led the charge on Monday, with some breaking out to new highs. Among the best performing non-leveraged ETFs of Monday, the ARK Genomic Revolution ETF...

Other symbols: XBI
3 years ago - ETF Trends

3 Biotech ETFs Up 10% Or More Over The Last Month

Something's been brewing in the health care sector, the second-largest group in the S&P 500.

Other symbols: ARKGBTEC
3 years ago - Benzinga

Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be

Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.

4 years ago - Bloomberg Markets and Finance

Best Growth ETFs for Q1 2020

The best Growth ETFs for Q1 2020 are XLK, BBC, and VGT.

Other symbols: VGTXLK
4 years ago - Investopedia

Best Healthcare ETFs for Q1 2020

The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.

Other symbols: KURESBIO
4 years ago - Investopedia

Biotech ETFs Are Not Riding the Wave from Coronavirus Panic

Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. A...

Other symbols: IBBXBI
4 years ago - ETF Trends

5 Best ETFs Of 2019

With just two trading days left in 2019, the SPDR S&P 500 ETF, the world's largest exchange traded fund, is higher by 29.19% this year, meaning the S&P 500 is on pace for its best annual performance s...

4 years ago - Benzinga